Savoldelli C, Le Page F, Santini J, Scortecci G, Odin G
Service d'ORL et de chirurgie maxillofaciale, hôpital Pasteur, 30, avenue de la Voie-Romaine, 06002 Nice cedex 01, France.
Rev Stomatol Chir Maxillofac. 2007 Dec;108(6):555-8. doi: 10.1016/j.stomax.2007.05.001. Epub 2007 Jul 13.
Bisphosphosnates are reference products used to treat osteoporosis, malignant bone disease, Paget's disease, and hypercalcemia. However these drugs seem to induce osteonecrosis of the jaws. This osteonecrosis is frequently observed and must be evoked in patients presenting with oral ulceration under bisphosphonate therapy.
We report the case of a long-term fully dental implanted patient treated by bisphosphonates who presented a maxillar ostenecrosis with no previous radiotherapy.
The risk factors and mechanism of this induced osteonecrosis are described. But could long term osseo-integrated dental implants be a triggering factor?
双膦酸盐是用于治疗骨质疏松症、恶性骨病、佩吉特氏病和高钙血症的参考药物。然而，这些药物似乎会诱发颌骨坏死。这种骨坏死经常被观察到，在接受双膦酸盐治疗且出现口腔溃疡的患者中必须予以考虑。
我们报告一例长期接受全口牙种植且接受双膦酸盐治疗的患者，该患者出现上颌骨坏死，既往无放疗史。
描述了这种诱发骨坏死的危险因素和机制。但是长期的骨整合牙种植体可能是一个触发因素吗？
